Thomas Smith
Stock Analyst at Leerink Partners
(2.39)
# 2,332
Out of 4,479 analysts
53
Total ratings
31.15%
Success rate
3.78%
Average return
Main Sectors:
Top Industries:
26 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTTB Q32 Bio | Initiates: Outperform | $54 | $18.05 | +199.17% | 1 | May 21, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $15.77 | +147.31% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $2.93 | +787.37% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $2.79 | +258.42% | 2 | Feb 21, 2024 | |
| ABVX Abivax | Initiates: Outperform | $20 | $13.50 | +48.15% | 1 | Nov 14, 2023 | |
| MORF Morphic Holding | Maintains: Outperform | $45 → $56 | $31.28 | +79.03% | 1 | Mar 8, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $435.49 | -0.11% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $41.62 | -13.50% | 1 | Feb 28, 2023 | |
| EQ Equillium | Maintains: Outperform | $12 → $7 | $0.68 | +929.41% | 3 | Feb 8, 2023 | |
| CNTB Connect Biopharma Holdings | Maintains: Outperform | $9 → $7 | $1.38 | +407.25% | 4 | Feb 8, 2023 | |
| IMVT Immunovant | Maintains: Outperform | $14 → $21 | $26.52 | -20.81% | 3 | Feb 6, 2023 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $40 → $45 | $12.16 | +270.07% | 2 | Jan 9, 2023 | |
| TRVI Trevi Therapeutics | Initiates: Outperform | $6 | $2.68 | +123.88% | 1 | Nov 22, 2022 | |
| MNKD MannKind | Maintains: Outperform | $5 → $6 | $5.03 | +19.28% | 2 | Nov 9, 2022 | |
| IMUX Immunic | Downgrades: Market Perform | $9 → $5 | $1.15 | +334.78% | 3 | Oct 21, 2022 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $17 | $40.15 | -57.66% | 1 | Aug 25, 2022 | |
| CLDX Celldex Therapeutics | Maintains: Outperform | $68 → $64 | $37.01 | +72.93% | 2 | Aug 9, 2022 | |
| PRTC PureTech Health | Maintains: Outperform | $66 → $70 | $24.20 | +189.26% | 5 | Aug 9, 2022 | |
| ETNB 89bio | Maintains: Outperform | $50 → $29 | $7.60 | +281.58% | 3 | Jul 11, 2022 | |
| ELDN Eledon Pharmaceuticals | Maintains: Outperform | $33 → $26 | $2.41 | +978.84% | 3 | Jun 1, 2022 | |
| ALLK Allakos | Maintains: Market Perform | $13 → $12 | $0.84 | +1,327.55% | 3 | May 12, 2022 | |
| VKTX Viking Therapeutics | Maintains: Outperform | $18 → $12 | $51.54 | -76.72% | 1 | Apr 28, 2022 | |
| GNFT Genfit | Maintains: Outperform | $15 → $10 | $3.97 | +151.89% | 2 | Apr 11, 2022 | |
| GLTO Galecto | Maintains: Outperform | n/a | $0.46 | - | 1 | Mar 16, 2021 | |
| ACRS Aclaris Therapeutics | Maintains: Outperform | n/a | $1.14 | - | 2 | Mar 4, 2021 | |
| KROS Keros Therapeutics | Initiates: Outperform | n/a | $42.81 | - | 1 | May 4, 2020 |
Q32 Bio
May 21, 2024
Initiates: Outperform
Price Target: $54
Current: $18.05
Upside: +199.17%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $15.77
Upside: +147.31%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $2.93
Upside: +787.37%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $2.79
Upside: +258.42%
Abivax
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $13.50
Upside: +48.15%
Morphic Holding
Mar 8, 2023
Maintains: Outperform
Price Target: $45 → $56
Current: $31.28
Upside: +79.03%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $435.49
Upside: -0.11%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $41.62
Upside: -13.50%
Equillium
Feb 8, 2023
Maintains: Outperform
Price Target: $12 → $7
Current: $0.68
Upside: +929.41%
Connect Biopharma Holdings
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.38
Upside: +407.25%
Immunovant
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $26.52
Upside: -20.81%
Viridian Therapeutics
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $12.16
Upside: +270.07%
Trevi Therapeutics
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $2.68
Upside: +123.88%
MannKind
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.03
Upside: +19.28%
Immunic
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.15
Upside: +334.78%
MoonLake Immunotherapeutics
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $40.15
Upside: -57.66%
Celldex Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $37.01
Upside: +72.93%
PureTech Health
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $24.20
Upside: +189.26%
89bio
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $7.60
Upside: +281.58%
Eledon Pharmaceuticals
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.41
Upside: +978.84%
Allakos
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $0.84
Upside: +1,327.55%
Viking Therapeutics
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $51.54
Upside: -76.72%
Genfit
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.97
Upside: +151.89%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: n/a
Current: $0.46
Upside: -
Aclaris Therapeutics
Mar 4, 2021
Maintains: Outperform
Price Target: n/a
Current: $1.14
Upside: -
Keros Therapeutics
May 4, 2020
Initiates: Outperform
Price Target: n/a
Current: $42.81
Upside: -